Physiomics enters the personalized medicine market. Anticipated new collaboration with Diatech Pharmacogenetics.

Physiomics enters the personalized medicine market. Anticipated new collaboration with Diatech Pharmacogenetics.

Physiomics is pleased to announce that it has signed a Heads of Terms agreement with Diatech Pharmacogenetics to negotiate a Collaboration Agreement. Under the terms of the anticipated Collaboration Agreement Physiomics and Diatech will develop an innovative in-silico platform to personalize cancer patient treatment.

This anticipated new in-silico platform will combine pharmacological information related to cancer drugs with genomic and physiological information about the patient, to predict which treatments and regimens are likely to lead to an increase in survival. The platform will initially be used to support physicians to make the best choice of available treatment options for patients. Ultimately, the software could be further developed to choose the right patient groups for clinical trials of new drugs.

Read more.